Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (FIZZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01493479
Recruitment Status : Unknown
Verified December 2011 by The Christie NHS Foundation Trust.
Recruitment status was:  Active, not recruiting
First Posted : December 16, 2011
Last Update Posted : December 16, 2011
Information provided by:
The Christie NHS Foundation Trust